Why have cancer neoantigen vaccines not yet achieved the same level of efficacy as other forms of immunotherapy? This question will be addressed by Jonathan S. Duke-Cohan from Harvard Medical School in a lecture taking place on 19 November 2026 at 3 pm in Prague as part of the Advances in Biomedical Research lecture series.
The lecture, entitled Why Aren’t Cancer Neoantigen Vaccines as Effective as Other Immunotherapies?, will explore the main challenges in developing effective cancer vaccines, including neoantigen identification and selection, tumour heterogeneity, impaired T-cell activation and mechanisms by which tumour cells evade immune responses. Particular attention will also be paid to the immunosuppressive tumour microenvironment and potential strategies for improving vaccine efficacy.
Jonathan S. Duke-Cohan is affiliated with Harvard Medical School and Dana-Farber Cancer Institute. His research focuses primarily on protein interactions involved in T-cell development, maturation, differentiation and activation.
When: 19 November 2026, 3–4 pm (registration from 2.45 pm)
Where: Cori Hall, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, U Nemocnice 5, Prague 2
For further information, please see the invitation.
